Patent ID: 7906485
Filing Date: 2011-03-15
Classification: A61K,A61P,B82Y,C07K

Abstract:
1. A method for treating a patient having pure red cell aplasia (PRCA), which method comprises administering once every 3 to 4 weeks to the patient a therapeutically effective amount of a compound that binds to an activates the erythropoietin receptor (EPO-R) wherein the compound comprises: (a) a first peptide monomer and a second peptide monomer, each of said first and second peptide monomers comprising the amino acid sequence (AcG)GLYACHMGPIT(1-nal)VCQPLR (SEQ ID NO:14); (b) a linker moiety covalently bonding the first peptide monomer to the second peptide monomer; and (c) a spacer moiety covalently joining the linker moiety and a poly(ethylene glycol) (PEG) moiety, said PEG moiety comprising a linear, unbranched PEG having molecular weight of 10,000 to 60,000 Daltons.